Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3103-3112

  Yu, Xiang ^a   Zou, Yanfen ^b   Li, Quan ^a   Mao, Yonghuan ^a   Zhu, Hui ^b   Huang, Guangming ^a   Ji, Guozhong ^a   Luo, Xiagang ^a   Yu, Chunzhao ^a   Zhang, Xiuhua ^a  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cholangiocarcinoma; Decorin; E cadherin; Migration; QBC939 cell

Indexed keywords

DECORIN; UVOMORULIN;

ADULT; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER INHIBITION; CANCER PROGNOSIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CADHERINS; CELL MOVEMENT; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DECORIN; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84898803452     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1402-y     Document Type: Article

References (34)

1. Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncol Basel. 2004;66:167-79. doi: 10.1159/000077991.
2. Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008;24:349-56. doi: 10.1097/MOG.0b013e3282fbf9b3.
3. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis. 1994;14:109-14. doi: 10.1055/s-2007- 1007302.
4. Nimura Y. Radical surgery: vascular and pancreatic resection for cholangiocarcinoma. HPB (Oxford). 2008;10:183-5. doi: 10.1080/13651820801992682.
5. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806-13.
6. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303-14. doi: 10.1016/S0140-6736(05)67530-7.
7. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341:1368-78. doi: 10.1056/NEJM199910283411807.
8. Dokduang H, Juntana S, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, et al. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. Tumour Biol. 2013. doi: 10.1007/s13277-013-0930-9.
9. Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem. 1999;274:4489-92.
10. Reed CC, Iozzo RV. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J. 2002;19:249-55. doi: 10.1023/A:1025383913444.
11. Hamid AS, Li J, Wang Y, Wu X, Ali HA, Du Z, et al. Recombinant human decorin upregulates p57KIP2 expression in HepG2 hepatoma cell lines. Mol Med Rep. 2013;8:511-6. doi: 10.3892/mmr.2013.1510.
12. Toole BP. Solubility of collagen fibrils formed in vitro in the presence of sulphated acid mucopolysaccharide-protein. Nature. 1969;222:872-3.
13. Stander M, Naumann U, Wick W, Weller M. Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res. 1999;296:221-7.
14. Bi X, Pohl NM, Qian Z, Yang GR, Gou Y, Guzman G, et al. Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis. 2012;33:326-30. doi: 10.1093/carcin/bgr293.
15. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A. 1995;92:7016-20.
16. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res. 2003;9:207-14.
17. De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV. Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem. 1996;271:18961-5.
18. Campioni M, Ambrogi V, Pompeo E, Citro G, Castelli M, Spugnini EP, et al. Identification of genes down-regulated during lung cancer progression: a cDNA array study. J Exp Clin Cancer Res. 2008;27:38. doi: 10.1186/1756-9966-27-38.
19. Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, et al. An antimetastatic role for decorin in breast cancer. Am J Pathol. 2008;173:844-55. doi: 10.2353/ajpath.2008.080275.
20. Bi X, Tong C, Dockendorff A, Bancroft L, Gallagher L, Guzman G, et al. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis. 2008;29:1435-40. doi: 10.1093/carcin/bgn141.
21. Hsu SM, Raine L. Protein A, avidin, and biotin in immunohistochemistry. J Histochem Cytochem. 1981;29:1349-53.
22. Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B, et al. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci U S A. 1999;96:3092-7.
23. Kresse H, Hausser H, Schonherr E. Small proteoglycans. Experientia. 1993;49:403-16.
24. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol. 1997;136:729-43.
25. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H. Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol. 1998;141:1277-86.
26. Zhu JX, Goldoni S, Bix G, Owens RT, McQuillan DJ, Reed CC, et al. Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem. 2005;280:32468-79. doi: 10.1074/jbc.M503833200.
27. Schonherr E, Sunderkotter C, Iozzo RV, Schaefer L. Decorin, a novel player in the insulin-like growth factor system. J Biol Chem. 2005;280:15767-72. doi: 10.1074/jbc.M500451200.
28. Guidetti GF, Bartolini B, Bernardi B, Tira ME, Berndt MC, Balduini C, et al. Binding of von Willebrand factor to the small proteoglycan decorin. Febs Lett. 2004;574:95-100. doi: 10.1016/j.febslet.2004.08.011.
29. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151-66. doi: 10.1007/s10555-008-9179-y.
30. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483-7. doi: 10.1126/science.1094291.
31. Hermiston ML, Wong MH, Gordon JI. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev. 1996;10:985-96.
32. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993;53:1696-701.
33. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 2006;10:437-49. doi: 10.1016/j.ccr.2006.09.013.
34. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol. 2003;19:207-35. doi: 10.1146/annurev.cellbio.19.011102. 111135.